Phase III Clinical Trial, long term treatment with TO-204 - Subcutaneous immunotherapy in patients with HDM-sensitized allergic rhinitis and asthma
Phase 3
- Conditions
- Allergic rhinitis or asthma sensitized to house dust mite
- Registration Number
- JPRN-jRCT2080221855
- Lead Sponsor
- TORII PHARMACEUTICAL CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
1) Positive test in RAST(specific anti-HDM IgE >= Class 2)
2) Positive skin prick/scratch test against HDM allergen
Exclusion Criteria
1) Patients with clinical symptoms of perennial rhinitis or asthma caused by allergen other than HDM
2) Patients with severe asthma
3) Patients with severe systemic diseases (i.e., auto-immune disease, immunocomplex disease, immunodeficient disease)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method